Genialis Inc. and Debiopharm SA have entered into an agreement to define and discover biomarkers within the DNA damage repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline.
Researchers from Renmin Hospital of Wuhan University have published results from their work that aimed to assess the role of exonuclease 1 (EXO1) in the progression of prostate cancer (PCa). A series of bioinformatic analyses revealed that EXO1 expression was higher in PCa tissue compared to normal tissue, and that high EXO1 expression predicted poor prognosis in PCa patients.
Increasing evidence exists suggesting plasma exosomal microRNAs (miRNAs) are involved in tumor progression, but their role in breast cancer is still unknown. Plasma exosome miRNA sequencing revealed that elevated levels of miR-361-3p were significantly correlated with malignant breast cancer progression in patients.
